Correlates of weight gain during long-term risperidone treatment in children and adolescents

Chinese Medicine

Bridget Zimmerman⁴  Diqiong Xie¹  Ginger Nicol²  Chadi Albert Calarge³ 

[1] Departments of Psychiatry, The University of Iowa Carver College of Medicine, 500 Newton Road, Iowa City, IA 52242, USA;Department of Psychiatry, Washington University School of Medicine, 660 South Euclid Ave, Campus Box 8134, St. Louis, MO 63110, USA;Departments of Psychiatry and Pediatrics, The University of Iowa Carver College of Medicine, 500 Newton Road, Iowa City, IA 52242, USA;Biostatistics Consultation Center, The University of Iowa College of Public Health, 200 Newton Road, Iowa City, IA 52242, USA

关键词: Predictors;    Risperidone;    Antipsychotics;    Obesity;    Weight gain;    Adolescent;    Child;   

Others  :  791360
DOI  :  10.1186/1753-2000-6-21

 received in 2012-02-17, accepted in 2012-05-29,  发布年份 2012

【 摘 要 】

Background

Most clinical trials of antipsychotics in children are brief, failing to address their long-term safety, particularly when taken concurrently with other psychotropics. This hypothesis-generating analysis evaluates potential correlates of weight gain in children receiving extended risperidone treatment.

Methods

Medically healthy 7–17 year-old patients treated with risperidone for six months or more were enrolled. Anthropometric measurements were conducted. Developmental and medication history was obtained from the medical record. Information related to birth weight, dietary intake, physical activity, and parental weight was collected. Mixed regression analyses explored the contribution of various demographic and clinical factors to age- and sex-adjusted weight and body mass index (BMI) z scores over the treatment period.

Results

The sample consisted of 110 patients (89% males) with a mean age of 11.8 years (sd = 2.9) upon enrollment. The majority had an externalizing disorder and received 0.03 mg/kg/day (sd = 0.02) of risperidone, for 2.5 years (sd = 1.7), to primarily target irritability and aggression (81%). Polypharmacy was common with 71% receiving psychostimulants, 50% selective serotonin reuptake inhibitors (SSRIs), and 32% α₂-agonists. Weight and BMI z score were positively correlated with baseline weight at the start of risperidone, treatment duration, and the weight-adjusted dose of risperidone but inversely associated with the weight-adjusted dose of psychostimulants and the concurrent use of SSRIs and α₂-agonists. The effect of risperidone dose appeared to attenuate as treatment extended while that of psychostimulants became more significant. The rate of change in weight (or BMI) z score prior to and within the first 12 weeks of risperidone treatment did not independently predict future changes neither did birth weight, postnatal growth, dietary intake, physical activity, or parental weight.

Conclusions

This comprehensive analysis exploring correlates of long-term weight (or BMI) change in risperidone-treated youths revealed that pharmacotherapy exerts significant but complex effects.

Trial Registration

Not applicable.

【 授权许可】

   
2012 Calarge et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

【 参考文献 】

• [1]Comer JS, Olfson M, Mojtabai R: National trends in child and adolescent psychotropic polypharmacy in office-based practice, 1996–2007. Journal of the American Academy of Child and Adolescent Psychiatry 2010, 49:1001-1010.
• [2]Olfson M, Crystal S, Huang C, Gerhard T: Trends in antipsychotic drug use by very young, privately insured children. J Am Acad Child Adolesc Psychiatry 2010, 49:13-23.
• [3]US FDA approves SEROQUEL for the pediatric treatment of schizophrenia and bipolar maniahttp://www.astrazeneca-us.com/?itemId=7659483 webcite.
• [4]Zyprexa: Medication Guide. http://www.fda.gov/downloads/Drugs/DrugSafety/UCM134700.pdf webcite.
• [5]FDA Approves the First Drug to Treat Irritability Associated with Autism, Risperdal. http://www.fda.gov/bbs/topics/NEWS/2006/NEW01485.html webcite.
• [6]Recommendation of Approvable Action for risperidone (Risperdal®) for the Treatment of Schizophrenia and Bipolar I Disorder in Pediatric Patients (response to PWR). http://www.fda.gov/downloads/Drugs/DevelopmentApprovalProcess/DevelopmentResources/UCM163241.pdf webcite
• [7]Findling RL: Atypical antipsychotic treatment of disruptive behavior disorders in children and adolescents. The J Clin Psychiatry 2008, 69(Suppl 4):9-14.
• [8]Pliszka SR, Crismon ML, Hughes CW, Corners CK, Emslie GJ, Jensen PS, McCracken JT, Swanson JM, Lopez M: The Texas Children's Medication Algorithm Project: revision of the algorithm for pharmacotherapy of attention-deficit/hyperactivity disorder. J A Acad Child Adolesc Psychiatry 2006, 45:642-657.
• [9]RUPP AN: Risperidone treatment of autistic disorder: longer-term benefits and blinded discontinuation after 6 months. Am J Psychiatry 2005, 162:1361-1369.
• [10]Reyes M, Buitelaar J, Toren P, Augustyns I, Eerdekens M: A randomized, double-blind, placebo-controlled study of risperidone maintenance treatment in children and adolescents with disruptive behavior disorders. Am J Psychiatry 2006, 163:402-410.
• [11]Calarge CA, Acion L, Kuperman S, Tansey M, Schlechte JA: Weight gain and metabolic abnormalities during extended risperidone treatment in children and adolescents. J Child Adolesc Psychopharmacol 2009, 19:101-109.
• [12]Correll CU, Manu P, Olshanskiy V, Napolitano B, Kane JM, Malhotra AK: Cardiometabolic risk of second-generation antipsychotic medications during first-time use in children and adolescents. JAMA 2009, 302:1765-1773.
• [13]Reaven GM: Insulin resistance: the link between obesity and cardiovascular disease. Endocrinol Metab Clin North Am 2008, 37:vii-viii.
• [14]Steinberger J, Daniels SR, Eckel RH, Hayman L, Lustig RH, McCrindle B, Mietus-Snyder ML: Progress and challenges in metabolic syndrome in children and adolescents: a scientific statement from the American Heart Association Atherosclerosis, Hypertension, and Obesity in the Young Committee of the Council on Cardiovascular Disease in the Young; Council on Cardiovascular Nursing; and Council on Nutrition, Physical Activity, and Metabolism. Circulation 2009, 119:628-647.
• [15]Correll CU, Carlson HE: Endocrine and metabolic adverse effects of psychotropic medications in children and adolescents. J Am Acad Child Adolesc Psychiatry 2006, 45:771-791.
• [16]Wilson D: Weight Gain Associated With Antipsychotic Drugs. City: The New York Times Company; 2009. [Book Weight Gain Associated With Antipsychotic Drugs (Editor ed.^eds.)]
• [17]Allison DB, Mentore JL, Heo M, Chandler LP, Cappelleri JC, Infante MC, Weiden PJ: Antipsychotic-induced weight gain: a comprehensive research synthesis. Am J Psychiatry 1999, 156:1686-1696.
• [18]Druet C, Ong KK: Early childhood predictors of adult body composition. Best Pract Res Clin Endocrinol Metab 2008, 22:489-502.
• [19]Monteiro PO, Victora CG: Rapid growth in infancy and childhood and obesity in later life–a systematic review. Obes Rev 2005, 6:143-154.
• [20]Barlow SE: Expert committee recommendations regarding the prevention, assessment, and treatment of child and adolescent overweight and obesity: summary report. Pediatrics 2007, 120(Suppl 4):S164-S192.
• [21]Fleischhaker C, Heiser P, Hennighausen K, Herpertz-Dahlmann B, Holtkamp K, Mehler-Wex C, Rauh R, Remschmidt H, Schulz E, Warnke A: Weight gain in children and adolescents during 45 weeks treatment with clozapine, olanzapine and risperidone. J Neural Transm 2008, 115:1599-1608.
• [22]Lipkovich I, Kryzhanovskaya LA, Robertson-Plouch C, Xu W, Watson SB, Tohen MF: Predicting substantial weight gain in olanzapine-treated adolescents with schizophrenia or bipolar disorder. IL: In American Academy of Child and Adolescent Psychiatry; Chicago; 2008.
• [23]Lipkovich I, Citrome L, Perlis R, Deberdt W, Houston JP, Ahl J, Hardy T: Early predictors of substantial weight gain in bipolar patients treated with olanzapine. J Clin Psychopharmacol 2006, 26:316-320.
• [24]Correll CU: Weight gain and metabolic effects of mood stabilizers and antipsychotics in pediatric bipolar disorder: a systematic review and pooled analysis of short-term trials. J Am Acad Child Adolesc Psychiatry 2007, 46:687-700.
• [25]Calarge CA, Zimmerman B, Xie D, Kuperman S, Schlechte JA: A cross-sectional evaluation of the effect of risperidone and selective serotonin reuptake inhibitors on bone mineral density in boys. J Clin Psychiatry 2010, 71:338-347.
• [26]Association AP: Diagnostic and Statistical Manual of Mental Disorders, Text Revision. 4th edition. Washington, DC: American Psychiatric Association; 2000.
• [27]Shaffer D, Fisher P, Lucas CP, Dulcan MK, Schwab-Stone ME: NIMH Diagnostic Interview Schedule for Children Version IV (NIMH DISC-IV): description, differences from previous versions, and reliability of some common diagnoses. J Am Acad Child Adolesc Psychiatry 2000, 39:28-38.
• [28]Achenbach TM, Rescorla LA: Manual for the ASEBA School-Age Froms & Profiles. Burlington, VT: Research Center for Children, Youth & Families; 2001.
• [29]Block G, Murphy M, Roullet JB, Wakimoto P, Crawford PB, Block T: Pilot validation of a FFQ for children 8–10 years (Abstract). City; 2000.
• [30]Ogden CL, Kuczmarski RJ, Flegal KM, Mei Z, Guo S, Wei R, Grummer-Strawn LM, Curtin LR, Roche AF, Johnson CL: Centers for Disease Control and Prevention 2000 growth charts for the United States: improvements to the 1977 National Center for Health Statistics version. Pediatrics 2002, 109:45-60.
• [31]Oken E, Kleinman KP, Rich-Edwards J, Gillman MW: A nearly continuous measure of birth weight for gestational age using a United States national reference. BMC Pediatr 2003, 3:1-10. BioMed Central Full Text
• [32]Faraone SV, Biederman J, Morley CP, Spencer TJ: Effect of stimulants on height and weight: a review of the literature. J Am Acad Child Adolesc Psychiatry 2008, 47:994-1009.
• [33]Swanson JM, Elliott GR, Greenhill LL, Wigal T, Arnold LE, Vitiello B, Hechtman L, Epstein JN, Pelham WE, Abikoff HB, et al.: Effects of stimulant medication on growth rates across 3 years in the MTA follow-up. J Am Acad Child Adolesc Psychiatry 2007, 46:1015-1027.
• [34]Simon V, van Winkel R, De Hert M: Are weight gain and metabolic side effects of atypical antipsychotics dose dependent? A literature review. J Clin Psychiatry 2009, 70:1041-1050.
• [35]Seroquel® (quetiapine fumarate) Tablets for the treatment of pediatric patients with schizophrenia (13–17 years old) or bipolar mania (10–17 years old). Briefing Document for Psychopharmacologic Drugs Advisory Committee, Meeting of June 9 and 10. 2009. http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/PsychopharmacologicDrugsAdvisoryCommittee/UCM164280.pdf webcite.
• [36]Haas M, Delbello MP, Pandina G, Kushner S, Van Hove I, Augustyns I, Quiroz J, Kusumakar V: Risperidone for the treatment of acute mania in children and adolescents with bipolar disorder: a randomized, double-blind, placebo-controlled study. Bipolar Disord 2009, 11:687-700.
• [37]Stockton G, Manos G, Forbes RA, Mankoski R: Effect of prior antipsychotic exposure on weight gain during aripiprazole treatment of irritability associated with autistic disorder. NY: In AACAP annual meeting; New York City; 2010.
• [38]Saddichha S, Ameen S, Akhtar S: Predictors of antipsychotic-induced weight gain in first-episode psychosis: conclusions from a randomized, double-blind, controlled prospective study of olanzapine, risperidone, and haloperidol. J Clin Psychopharmacol 2008, 28:27-31.
• [39]Findling RL, Nyilas M, Forbes RA, McQuade RD, Jin N, Iwamoto T, Ivanova S, Carson WH, Chang K: Acute treatment of pediatric bipolar I disorder, manic or mixed episode, with aripiprazole: a randomized, double-blind, placebo-controlled study. J Clin Psychiatry 2009, 70:1441-1451.
• [40]Calarge CA, Ellingrod VL, Acion L, Miller DD, Moline J, Tansey MJ, Schlechte JA: Variants of the dopamine D2 receptor gene and risperidone-induced hyperprolactinemia in children and adolescents. Pharmacogenet Genomics 2009, 19:373-382.
• [41]Calarge C, Xie D, Zimmerman B: Clinical Predictors of Weight Change During Long-Term Risperidone Treatment. FL: Boca Raton; 2011.
• [42]Penzner JB, Dudas M, Saito E, Olshanskiy V, Parikh UH, Kapoor S, Chekuri R, Gadaleta D, Avedon J, Sheridan EM, et al.: Lack of effect of stimulant combination with second-generation antipsychotics on weight gain, metabolic changes, prolactin levels, and sedation in youth with clinically relevant aggression or oppositionality. J Child Adolesc Psychopharmacol 2009, 19:563-573.
• [43]Armenteros JL, Lewis JE, Davalos M: Risperidone augmentation for treatment-resistant aggression in attention-deficit/hyperactivity disorder: a placebo-controlled pilot study. J Am Acad Child Adolesc Psychiatry 2007, 46:558-565.
• [44]Goldstein BJ, Goodnick PJ: Selective serotonin reuptake inhibitors in the treatment of affective disorders--III. Tolerability, safety and pharmacoeconomics. J Psychopharmacol 1998, 12:S55-S87.
• [45]Wagner KD, Robb AS, Findling RL, Jin J, Gutierrez MM, Heydorn WE: A randomized, placebo-controlled trial of citalopram for the treatment of major depression in children and adolescents. Am J Psychiatry 2004, 161:1079-1083.
• [46]Wagner KD, Ambrosini P, Rynn M, Wohlberg C, Yang R, Greenbaum MS, Childress A, Donnelly C, Deas D: Efficacy of sertraline in the treatment of children and adolescents with major depressive disorder: two randomized controlled trials. JAMA 2003, 290:1033-1041.
• [47]Nilsson M, Joliat MJ, Miner CM, Brown EB, Heiligenstein JH: Safety of subchronic treatment with fluoxetine for major depressive disorder in children and adolescents. J Child Adolesc Psychopharmacol 2004, 14:412-417.
• [48]Calarge C, Kuperman S: Fluoxetine for depression relapse prevention. J Am Acad Child Adolesc Psychiatry 2005, 44:966-967. author reply 967–968
• [49]Heykants J, Huang ML, Mannens G, Meuldermans W, Snoeck E, Van Beijsterveldt L, Van Peer A, Woestenborghs R: The pharmacokinetics of risperidone in humans: a summary. J Clin Psychiatry 1994, 55(Suppl):13-17.
• [50]Calarge CA, Miller DD: Predictors of risperidone and 9-hydroxyrisperidone serum concentration in children and adolescents. J Child Adolesc Psychopharmacology 2011, 21:163-169.
• [51]Meyer JH, Wilson AA, Sagrati S, Hussey D, Carella A, Potter WZ, Ginovart N, Spencer EP, Cheok A, Houle S: Serotonin transporter occupancy of five selective serotonin reuptake inhibitors at different doses: an [11 C]DASB positron emission tomography study. Am J Psychiatry 2004, 161:826-835.
• [52]Suhara T, Takano A, Sudo Y, Ichimiya T, Inoue M, Yasuno F, Ikoma Y, Okubo Y: High levels of serotonin transporter occupancy with low-dose clomipramine in comparative occupancy study with fluvoxamine using positron emission tomography. Arch Gen Psychiatry 2003, 60:386-391.
• [53]Vanina Y, Podolskaya A, Sedky K, Shahab H, Siddiqui A, Munshi F, Lippmann S: Body weight changes associated with psychopharmacology. Psychiatr Serv 2002, 53:842-847.
• [54]Dulloo AG: Regulation of fat storage via suppressed thermogenesis: a thrifty phenotype that predisposes individuals with catch-up growth to insulin resistance and obesity. Horm Res 2006, 65(Suppl 3):90-97.
• [55]Basson BR, Kinon BJ, Taylor CC, Szymanski KA, Gilmore JA, Tollefson GD: Factors influencing acute weight change in patients with schizophrenia treated with olanzapine, haloperidol, or risperidone. J Clin Psychiatry 2001, 62:231-238.
• [56]Fountaine RJ, Taylor AE, Mancuso JP, Greenway FL, Byerley LO, Smith SR, Most MM, Fryburg DA: Increased food intake and energy expenditure following administration of olanzapine to healthy men. Obesity (Silver Spring) 2010, 18:1646-1651.
• [57]Gothelf D, Falk B, Singer P, Kairi M, Phillip M, Zigel L, Poraz I, Frishman S, Constantini N, Zalsman G, et al.: Weight gain associated with increased food intake and low habitual activity levels in male adolescent schizophrenic inpatients treated with olanzapine. Am J Psychiatry 2002, 159:1055-1057.
• [58]Safer DJ, Allen RP, Barr E: Growth rebound after termination of stimulant drugs. J Pediatr 1975, 86:113-116.
• [59]Lipkovich I, Jacobson JG, Hardy TA, Hoffmann VP: Early evaluation of patient risk for substantial weight gain during olanzapine treatment for schizophrenia, schizophreniform, or schizoaffective disorder. BMC Psychiatry 2008, 8:78. BioMed Central Full Text
• [60]Arterburn D, Ichikawa L, Ludman EJ, Operskalski B, Linde JA, Anderson E, Rohde P, Jeffery RW, Simon GE: Validity of Clinical Body Weight Measures as Substitutes for Missing Data in a Randomized Trial. Obes Res Clin Pract 2008, 2:277-281.
• [61]Aman MG, Binder C, Turgay A: Risperidone effects in the presence/absence of psychostimulant medicine in children with ADHD, other disruptive behavior disorders, and subaverage IQ. J Child Adolesc Psychopharmacol 2004, 14:243-254.
• [62]McCracken JT, McGough J, Shah B, Cronin P, Hong D, Aman MG, Arnold LE, Lindsay R, Nash P, Hollway J, et al.: Risperidone in children with autism and serious behavioral problems. N Engl J Med 2002, 347:314-321.
• [63]Scahill L, Leckman JF, Schultz RT, Katsovich L, Peterson BS: A placebo-controlled trial of risperidone in Tourette syndrome. Neurology 2003, 60:1130-1135.
• [64]Sikich L, Frazier JA, McClellan J, Findling RL, Vitiello B, Ritz L, Ambler D, Puglia M, Maloney AE, Michael E, et al.: Double-blind comparison of first- and second-generation antipsychotics in early-onset schizophrenia and schizo-affective disorder: findings from the treatment of early-onset schizophrenia spectrum disorders (TEOSS) study. Am J Psychiatry 2008, 165:1420-1431.
• [65]Gebhardt S, Theisen FM, Haberhausen M, Heinzel-Gutenbrunner M, Wehmeier PM, Krieg JC, Kuhnau W, Schmidtke J, Remschmidt H, Hebebrand J: Body weight gain induced by atypical antipsychotics: an extension of the monozygotic twin and sib pair study. J Clin Pharm Ther 2010, 35:207-211.
• [66]De Luca V, Mueller DJ, de Bartolomeis A, Kennedy JL: Association of the HTR2C gene and antipsychotic induced weight gain: a meta-analysis. Int J Neuropsychopharmacol 2007, 10:697-704.
• [67]Calarge CA, Ellingrod VL, Zimmerman B, Acion L, Sivitz WI, Schlechte JA: Leptin gene -2548 G/A variants predict risperidone-associated weight gain in children and adolescents. Psychiatr Genet 2009, 19:320-327.